Next 10 |
home / stock / sprc / sprc articles
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceu...
SciSparc Ltd. (NASDAQ:SPRC) announced on Friday that it has enrolled the first patient in the company's clinical trial assessing the efficacy ...
The Company's most recent patent further solidifies its position, complementing existing grants in the U.S., Japan, Australia and other key ju...
New patent applications build upon Clearmind's broad IP protection in the psychedelic space Vancouver, Canada, Feb. 27, 2024 (GLOBE NEWSWIR...
On Tuesday, Clearmind Medicine Inc (NASDAQ:CMND) submitted three additional patent applications under the international Patent Cooperatio...
The ongoing collaboration between SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) (CSE:CMND) (FSE: CWY) resulted in the Tuesd...
SciSparc Ltd. (NASDAQ:SPRC) and Clearmind Medicine Inc. (NASDAQ:CMND) shares are trading higher Tuesday after the companies announced the submissio...
Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results. Fluor posted adjusted earnings of 68...
Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $1...
News, Short Squeeze, Breakout and More Instantly...
SciSparc Ltd. Company Name:
SPRC Stock Symbol:
NASDAQ Market:
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that as part ...
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the develo...
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceu...